COVID-19 vaccines and IP waiver proposals: One year on, where are we now?

A lot has changed over the last year since IP waiver proposals were first put forward - notably a massive rise in the production of COVID-19 vaccines. Komal Kalha of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) tells us more ahead of her presentation this week during BioPharma-Reporter's Manufacture of Vaccines webinar.